An Intestine-on-a-Chip Model of Plug-and-Play Modularity to Study Inflammatory Processes.

barrier integrity high-throughput intestinal inflammation microfluidics plug-and-play complexity

Journal

SLAS technology
ISSN: 2472-6311
Titre abrégé: SLAS Technol
Pays: United States
ID NLM: 101697564

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 25 6 2020
medline: 29 10 2021
entrez: 25 6 2020
Statut: ppublish

Résumé

Development of efficient drugs and therapies for the treatment of inflammatory conditions in the intestine is often hampered by the lack of reliable, robust, and high-throughput in vitro and in vivo models. Current models generally fail to recapitulate key aspects of the intestine, resulting in low translatability to the human situation. Here, an immunocompetent 3D perfused intestine-on-a-chip platform was developed and characterized for studying intestinal inflammation. Forty independent polarized 3D perfused epithelial tubular structures were grown from cells of mixed epithelial origin, including enterocytes (Caco-2) and goblet cells (HT29-MTX-E12). Immune cells THP-1 and MUTZ-3, which can be activated, were added to the system and assessed for cytokine release. Intestinal inflammation was mimicked through exposure to tumor necrosis factor-α (TNFα) and interleukin (IL)-1β. The effects were quantified by measuring transepithelial electrical resistance (TEER) and proinflammatory cytokine secretion on the apical and basal sides. Cytokines induced an inflammatory state in the culture, as demonstrated by the impaired barrier function and increased IL-8 secretion. Exposure to the known anti-inflammatory drug TPCA-1 prevented the inflammatory state. The model provides biological modularity for key aspects of intestinal inflammation, making use of well-established cell lines. This allows robust assays that can be tailored in complexity to serve all preclinical stages in the drug discovery and development process.

Identifiants

pubmed: 32576063
doi: 10.1177/2472630320924999
pmc: PMC7684793
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

585-597

Références

World J Gastroenterol. 2012 Nov 7;18(41):5848-61
pubmed: 23139600
Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):E7-15
pubmed: 26668389
EMBO J. 2015 May 5;34(9):1149-63
pubmed: 25792515
Inflamm Bowel Dis. 2014 Jan;20(1):166-75
pubmed: 23974993
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
AAPS J. 2018 Aug 14;20(5):90
pubmed: 30109442
Langmuir. 2012 Dec 18;28(50):17349-62
pubmed: 23171215
J Lab Autom. 2015 Apr;20(2):107-26
pubmed: 25586998
Cytokine. 2016 Jan;77:44-9
pubmed: 26520877
Mayo Clin Proc. 2019 Jan;94(1):155-165
pubmed: 30611442
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):205-17
pubmed: 25732745
Biotechnol Bioeng. 2012 Sep;109(9):2173-8
pubmed: 22488418
Nat Genet. 2015 Sep;47(9):979-986
pubmed: 26192919
Sci Rep. 2017 May 03;7:46790
pubmed: 28467395
J Health Econ. 2016 May;47:20-33
pubmed: 26928437
Ann Allergy Asthma Immunol. 1995 Jul;75(1):33-40
pubmed: 7621058
Gastroenterology. 1989 Mar;96(3):736-49
pubmed: 2914637
Immunology. 1988 Feb;63(2):299-302
pubmed: 3350575
Stem Cells Int. 2019 Mar 19;2019:8010645
pubmed: 31015842
Mol Cancer Ther. 2018 Jul;17(7):1464-1474
pubmed: 29654069
Nat Commun. 2017 Aug 15;8(1):262
pubmed: 28811479
J Theor Biol. 2011 Jun 21;279(1):63-73
pubmed: 21440560
Altern Lab Anim. 2005 Dec;33(6):603-18
pubmed: 16372835
Sci Rep. 2018 Feb 13;8(1):2871
pubmed: 29440725
PLoS One. 2013 Jul 15;8(7):e68761
pubmed: 23869232
J Cell Sci. 1993 Nov;106 ( Pt 3):771-83
pubmed: 8308060
Lab Chip. 2012 Jun 21;12(12):2165-74
pubmed: 22434367
J Immunol. 1999 Sep 15;163(6):3484-90
pubmed: 10477621
Science. 2013 Jun 7;340(6137):1190-4
pubmed: 23744940
Blood. 2002 Jul 15;100(2):701-3
pubmed: 12091369
Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13780-5
pubmed: 17699621
Gut. 1993 Dec;34(12):1705-9
pubmed: 8031350
Adv Healthc Mater. 2019 Nov;8(21):e1900968
pubmed: 31592579
Eur J Med Res. 2000 Aug 18;5(8):347-55
pubmed: 10958768
Health Econ. 2010 Feb;19(2):130-41
pubmed: 19247981
J Comp Physiol B. 2008 Aug;178(6):673-90
pubmed: 18401586
Int J Mol Sci. 2019 Nov 12;20(22):
pubmed: 31726729
Nat Rev Immunol. 2009 May;9(5):313-23
pubmed: 19343057
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Pharmacol Res. 2005 Nov;52(5):422-8
pubmed: 16118056
Gut. 2015 Jun;64(6):911-20
pubmed: 25007816

Auteurs

Linda Gijzen (L)

Mimetas BV, Leiden, The Netherlands.

Diego Marescotti (D)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Elisa Raineri (E)

Mimetas BV, Leiden, The Netherlands.

Arnaud Nicolas (A)

Mimetas BV, Leiden, The Netherlands.

Henriette L Lanz (HL)

Mimetas BV, Leiden, The Netherlands.

Diego Guerrera (D)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Remko van Vught (R)

Mimetas BV, Leiden, The Netherlands.

Jos Joore (J)

Mimetas BV, Leiden, The Netherlands.

Paul Vulto (P)

Mimetas BV, Leiden, The Netherlands.

Manuel C Peitsch (MC)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Julia Hoeng (J)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Giuseppe Lo Sasso (G)

PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.

Dorota Kurek (D)

Mimetas BV, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH